NEW YORK (GenomeWeb News) – Merck Serono and Compugen jointly announced today the formation of a new biomarker discovery firm focused on prediction of drug-induced toxicity.

The new venture, called Neviah Genomics, will operate out of the Merck Serono Israel Bioincubator and will receive funding from Merck Serono Ventures. Tel Aviv, Israel-based Compugen will provide predictive discovery technologies to the venture and will receive an undisclosed equity stake in the company and rights to royalties from potential future sales. Further terms of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.